What happened with MDWD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MediWound’s only approved product, NexoBrid, is applied to deep burns to remove dead tissue using enzymes derived from pineapple stems. Burn centers and hospital burn units buy it directly in Europe and Israel, while distributors serve other markets. In North America, exclusive partner Vericel sells NexoBrid; MediWound supplies the drug and receives payments for those supplies, sales royalties and potential sales milestones. Its U.S. commercial business therefore depends heavily on Vericel. EscharEx, its treatment for chronic and hard-to-heal wounds, remains in clinical development.
Paid development services have generated more revenue than product sales, with U.S. government customers BARDA and DoW/MTEC together supplying most revenue. Their contracts supported NexoBrid development, emergency preparedness and a temperature-stable formulation for military field care. Those contracts expired in 2025, so that revenue stream depends on securing further funded work rather than simply continuing the former contracts.
Production relies on one site in Yavne, Israel, and on Challenge Bioproducts Corporation in Taiwan as the sole supplier of a key enzyme starting material. Commercial supply from MediWound’s expanded facility requires regulatory approval. Israeli rules also require prior approval to transfer technology or manufacturing rights developed with Israel Innovation Authority funding outside Israel, limiting its ability to move that work abroad.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
MediWound also relies heavily on U.S. government development funding and on CBC to supply the bromelain starting material for its enzyme therapies.
MediWound depends on Vericel to buy NexoBrid and market it exclusively in North America, earning supply revenue, royalties and potential sales-milestone payments. Watch Vericel’s NexoBrid sales through specialty distributors to hospitals and burn centers: those sales drive royalties, while its orders from MediWound drive supply revenue.
Smith & Nephew’s SANTYL ointment removes dead tissue from chronic wounds using enzymes—the established treatment MediWound’s still-developing EscharEx would challenge. SANTYL’s U.S. sales show the incumbent revenue base at stake, but EscharEx, if approved, would still need to persuade physicians to change treatments.
MiMedx sells wound-healing tissue grafts to the clinical market MediWound is targeting with EscharEx, and supports the program through research collaboration. Its U.S. wound-treatment sales offer a view of the customer market EscharEx aims to enter, rather than a direct source of MediWound revenue.
Solventum already sells negative-pressure wound treatments and advanced dressings into the wound-care market MediWound’s EscharEx aims to enter, and supports its research program. Watch those wound-care products within Solventum’s MedSurg business, rather than its dental products or software, for a view of that shared market.
MiMedx Group, Inc earningsMDXG
MiMedx's U.S. wound-treatment business offers a view of demand in the clinical market EscharEx aims to enter, but it is not direct revenue for MediWound.
Read any disclosed U.S. wound-treatment sales alongside the direction of MiMedx's overall business. Stronger wound-treatment sales would suggest firmer demand in the clinical market EscharEx aims to enter, though MiMedx sells different products; weaker sales would point to a tougher demand backdrop for MediWound.
Vericel Corporation earningsVCEL
Vericel's report will show how NexoBrid is selling in North America; those sales drive royalties and influence the supply revenue Vericel generates when it orders product from MediWound.
Read Vericel's NexoBrid sales alongside MediWound's product-sales revenue. Stronger sales can mean more royalties and supply revenue for MediWound; weaker sales can pressure both. The figures may not move together because supply revenue depends on when Vericel places orders.
MediWound Ltd. earningsThis company
With its BARDA and MTEC contracts expired, MediWound needs NexoBrid sales and related royalties to fill the gap, and this report will show whether commercial revenue is doing so.
Read product sales and license-and-royalty revenue alongside development-services revenue. If the commercial lines hold up as contract revenue falls, NexoBrid is carrying more of the business through hospital and distributor sales and Vericel-linked supply revenue and royalties. If they do not, MediWound has fewer sources of revenue as contract work runs off.
